Morningstar

Eli Lilly, Nimbus Partner to Develop, License Oral Obesity Treatment

Provided by Dow Jones

By Elias Schisgall 




  Eli Lilly and Nimbus Therapeutics have entered into a multi-year collaboration and exclusive licensing agreement to develop an oral treatment for obesity and other metabolic diseases. 



  Nimbus, an artificial-intelligence drug discovery company, said Tuesday that it is eligible for upfront and near-term milestone payments totaling $55 million, as well as up to $1.3 billion in development, commercial and sales milestones alongside tiered royalties on global net sales. 



  The two companies had previously collaborated on targeting AMPK in cardiometabolic diseases. 



  "We are pleased to deepen our collaboration with Nimbus, a team that has demonstrated exceptional ability to tackle complex drug discovery challenges," said Ruth Gimeno, who is vice president of Eli Lilly's diabetes and metabolic research and development group. "Working together to develop this novel obesity therapy represents an important addition to Lilly's efforts to advance innovative treatment options for patients with metabolic disorders." 





  Write to Elias Schisgall at elias.schisgall@wsj.com 





  (END) Dow Jones Newswires



  January 06, 2026 12:17 ET (17:17 GMT)


Copyright (c) 2026 Dow Jones & Company, Inc.
  

					The articles, information, and content displayed on this webpage may
					include materials prepared and provided by third parties. Such
					third-party content is offered for informational purposes only and
					is not endorsed, reviewed, or verified by Morningstar.
				
 

					Morningstar makes no representations or warranties regarding the
					accuracy, completeness, timeliness, or reliability of any third-party
					content displayed on this site. The views and opinions expressed in
					third-party content are those of the respective authors and do not
					necessarily reflect the views of Morningstar, its affiliates, or employees.
				
 

					Morningstar is not responsible for any errors, omissions, or delays
					in this content, nor for any actions taken in reliance thereon.
					Users are advised to exercise their own judgment and seek independent
					financial advice before making any decisions based on such content.
					The third-party providers of this content are not affiliated with
					Morningstar, and their inclusion on this site does not imply any
					form of partnership, agency, or endorsement.
				
 

				Popular
				
 
  
 
 
 
 
3 Stocks to Sell and 3 Stocks to Buy for November
 
Plus, whether Microsoft, Alphabet, or Amphenol look attractive after earnings.  
 
 
David Sekera, CFA and Sarah Hansen 
 
 
 
This Once-Hot AI Stock Now Looks Deeply Undervalued
 
This chip stock looks cheap at a 30% discount, and its biggest growth years could still be ahead. 
 
 
William Kerwin, CFA 
 
 
 
The 10 Best Companies to Invest in Now
 
The stocks of these high-quality companies look cheap today. 
 
 
Tori Brovet 
 
 
 
He Tried Shorting Jim Cramer’s Stock Picks. It Cost Him More Than Money
 
Historian Joseph Moore explores why a promising product can fail as an investment and why beating the market may not be worth the effort. 
 
 
Christine Benz and Amy C. Arnott, CFA 
 
 
 
3 of the Best Dividend Stocks to Own
 
These dividend stocks with economic moats offer durable payouts. 
 
 
Susan Dziubinski 
 
 
 
 

			Sponsor Center